Alveus Therapeutics emerged with a $159.8–$160 million Series A to advance a Phase‑2 ready obesity candidate that targets the same two pathways as Amgen’s MariTide, with claims of potential dosing advantages. The financing will also support additional molecules aimed at competing with programs from Roche and Novo Nordisk in the weight‑loss space. Alveus will push its lead into Phase 2 while exploring indications and dosing regimens that could differentiate the drug commercially. The raise underscores continued investor interest in obesity therapeutics despite recent data showing rapid weight regain after stopping treatment; durable efficacy and tolerability remain strategic priorities. Clarification: 'MariTide' refers to Amgen’s investigational tirzepatide‑like agent; many entrants are pursuing multi‑agonist incretin approaches.